|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bonci D, Coppola V, Patrizii M, Addario A,
Cannistraci A, Francescangeli F, Pecci R, Muto G, Collura D, Bedini
R, et al: A microRNA code for prostate cancer metastasis. Oncogene.
35:1180–1192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guinney J, Wang T, Laajala TD, Winner KK,
Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, et
al: Prediction of overall survival for patients with metastatic
castration-resistant prostate cancer: Development of a prognostic
model through a crowdsourced challenge with open clinical trial
data. Lancet Oncol. 18:132–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabris L, Ceder Y, Chinnaiyan AM, Jenster
GW, Sorensen KD, Tomlins S, Visakorpi T and Calin GA: The potential
of MicroRNAs as prostate cancer biomarkers. Eur Urol. 70:312–322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Endzeliņš E, Melne V, Kalniņa Z,
Lietuvietis V, Riekstiņa U, Llorente A and Linē A: Diagnostic,
prognostic and predictive value of cell-free miRNAs in prostate
cancer: A systematic review. Mol Cancer. 15:412016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.PubMed/NCBI
|
|
9
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watahiki A and Wang Y, Morris J, Dennis K,
O'Dwyer HM, Gleave M, Gout PW and Wang Y: MicroRNAs associated with
metastatic prostate cancer. PLoS One. 6:e249502011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
López-Romero P: Pre-processing and
differential expression analysis of Agilent microRNA arrays using
the AgiMicroRna Bioconductor library. BMC Genomics. 12:642011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smyth GK: Limma: Linear models for
microarray dataBioinformatics and Computational Biology Solutions
Using R and Bioconductor. Springer; pp. 397–420. 2005, View Article : Google Scholar
|
|
15
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc Ser B (Methodological). 57:289–300.
1995.
|
|
16
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human microRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang LY, Lee Ho-Fun V, Wong AM, Kwong DL,
Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY and Fu L:
MicroRNA-144 promotes cell proliferation, migration and invasion in
nasopharyngeal carcinoma through repression of PTEN.
Carcinogenesis. 34:454–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lopezcamacho C, van Wijnen AJ, Lian JB,
Stein JL and Stein GS: (CBFβ) and the leukemogenic fusion protein
CBFβ-SMMHC associate with mitotic chromosomes to epigenetically
regulate ribosomal gene. J Cell Biochem. 115:2155–2164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin VK, Wang D, Lee I, Vasquez D, Fagelson
JE and McConnell JD: Myosin heavy chain gene expression in normal
and hyperplastic human prostate tissue. Prostate. 44:193–203. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grisanzio C, Werner L, Takeda D, Awoyemi
BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R,
Schinzel AC, et al: Genetic and functional analyses implicate the
NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.
Proc Natl Acad Sci USA. 109:11252–11257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zilleßen P, Celner J, Kretschmann A,
Pfeifer A, Racké K and Mayer P: Metabolic role of dipeptidyl
peptidase 4 (DPP4) in primary human (pre)adipocytes. Sci Rep.
6:230742016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong J, Kankanala S and Rajagopalan S:
Dipeptidyl peptidase-4 inhibition: Insights from the bench and
recent clinical studies. Curr Opin Lipidol. 27:484–492. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilson MJ, Ruhland AR, Quast BJ, Reddy PK,
Ewing SL and Sinha AA: Dipeptidylpeptidase IV activities are
elevated in prostate cancers and adjacent benign hyperplastic
glands. J Androl. 21:220–226. 2000.PubMed/NCBI
|
|
27
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to
suppress the proliferation, invasion, and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kobayashi N, Uemura H, Nagahama K, Okudela
K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, et al:
Identification of miR-30d as a novel prognostic maker of prostate
cancer. Oncotarget. 3:1455–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ribon V, Herrera R, Kay BK and Saltiel AR:
A role for CAP, a novel, multifunctional Src homology 3
domain-containing protein in formation of actin stress fibers and
focal adhesions. J Biol Chem. 273:4073–4080. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vanaja DK, Ballman KV, Morlan BW, Cheville
JC, Neumann RM, Lieber MM, Tindall DJ and Young CY: PDLIM4
repression by hypermethylation as a potential biomarker for
prostate cancer. Clin Cancer Res. 12:1128–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stoclet JC, Keravis T, Komas N and Lugnier
C: Section Review: Cardiovascular & Renal: Cyclic nucleotide
phosphodiesterases as therapeutic targets in cardiovascular
diseases. Expert Opinion Investigational Drugs. 4:19952008.
|
|
32
|
Uckert S, Küthe A, Jonas U and Stief CG:
Characterization and functional relevance of cyclic nucleotide
phosphodiesterase isoenzymes of the human prostate. J Urol.
166:2484–2490. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tohtong R, Phattarasakul K, Jiraviriyakul
A and Sutthiphongchai T: Dependence of metastatic cancer cell
invasion on MLCK-catalyzed phosphorylation of myosin regulatory
light chain. Prostate Cancer Prostatic Dis. 6:212–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang
YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly
enhances drug sensitivity in chronic lymphocytic leukemia cells via
targeting multiple anti-apoptosis genes. Carcinogenesis.
33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhai XF, Fang FF, Liu Q, Meng YB, Guo YY
and Chen Z: MiR-181a contributes to bufalin-induced apoptosis in
PC-3 prostate cancer cells. BMC Complement Altern Med. 13:3252013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su SF, Chang YW, Andreu-Vieyra C, Fang JY,
Yang Z, Han B, Lee AS and Liang G: miR-30d, miR-181a and
miR-199a-5p cooperatively suppress the endoplasmic reticulum
chaperone and signaling regulator GRP78 in cancer. Oncogene.
32:4694–4701. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen WT, Zhu G, Pfaffenbach K, Kanel G,
Stiles B and Lee AS: GRP78 as a regulator of liver steatosis and
cancer progression mediated by loss of the tumor suppressor PTEN.
Oncogene. 33:4997–5005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yekta S, Shih IH and Bartel DP:
MicroRNA-directed cleavage of HOXB8 mRNA. Science. 304:594–596.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Waltregny D, Alami Y, Clausse N, de Leval
J and Castronovo V: Overexpression of the homeobox gene HOXC8 in
human prostate cancer correlates with loss of tumor
differentiation. Prostate. 50:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miller GJ, Miller HL, van Bokhoven A,
Lambert JR, Werahera PN, Schirripa O, Lucia MS and Nordeen SK:
Aberrant HOXC expression accompanies the malignant phenotype in
human prostate. Cancer Res. 63:5879–5888. 2003.PubMed/NCBI
|
|
41
|
Chandran UR, Ma C, Dhir R, Bisceglia M,
Lyons-Weiler M, Liang W, Michalopoulos G, Becich M and Monzon FA:
Gene expression profiles of prostate cancer reveal involvement of
multiple molecular pathways in the metastatic process. BMC Cancer.
7:642007. View Article : Google Scholar : PubMed/NCBI
|
